Agreement of immunosuppression regimens described in medicare pharmacy claims with the Organ Procurement and Transplantation Network survey

Paula M. Stirnemann, Steven K. Takemoto, Mark A. Schnitzler, Daniel Brennan, Kevin C. Abbott, Paolo Salvalaggio, Thomas E. Burroughs, Jeffrey A. Gavard, Lisa M. Willoughby, Krista L. Lentine

Research output: Contribution to journalReview article

Abstract

The Organ Procurement and Transplantation Network (OPTN) collects intermittent survey data on immunosuppressive medication use that are studied frequently as research measures. Pharmacy billing claims may provide an accurate measure of immunosuppression use over time. Herein is characterized the agreement of Medicare pharmacy claims for immunosuppressive medications with OPTN reports. Data were drawn from the United States Renal Data System. Participants received a kidney transplant in 2000 to 2001 and had an OPTN record and a Medicare pharmacy claim for an immunosuppressive drug at transplant discharge and 6 mo and 1 yr after transplantation. The concordance (K) of the OPTN and claims (±30 d of survey) for indicated medication use was compared, and sensitivity, specificity, and predictive values for claims were computed, assuming OPTN as a "gold standard." Clinical trial participation and regimen changes were examined as explanations for discordance. A total of 4357 eligible subjects were identified. Concordance over observation ranged from excellent for calcineurin inhibitors (κ > 0.86) to generally very good for adjunctive agents (κ = 0.49 to 0.75) to poor for corticosteroids (κ < 0.15). Claims demonstrated high positive predictive values (≤97%) but low negative predictive values (≤13%) for OPTN-reported corticosteroid use. Regimen changes (28 to 75%) but not clinical trial participation (≤21%) were identified frequently among cases with discordant indications of nonsteroid medication use. Close agreement of Medicare billing claims and the OPTN for indicated use of nonsteroid immunosuppressive medications supports both as useful measures of drug exposure. Low detection rates of OPTN-indicated corticosteroid use within claims require further examination.

Original languageEnglish (US)
Pages (from-to)2299-2306
Number of pages8
JournalJournal of the American Society of Nephrology
Volume17
Issue number8
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Fingerprint

Tissue and Organ Procurement
Organ Transplantation
Medicare
Immunosuppression
Immunosuppressive Agents
Adrenal Cortex Hormones
Clinical Trials
Transplants
Kidney
Surveys and Questionnaires
Information Systems
Pharmaceutical Preparations
Transplantation
Observation
Sensitivity and Specificity
Research

ASJC Scopus subject areas

  • Nephrology

Cite this

Agreement of immunosuppression regimens described in medicare pharmacy claims with the Organ Procurement and Transplantation Network survey. / Stirnemann, Paula M.; Takemoto, Steven K.; Schnitzler, Mark A.; Brennan, Daniel; Abbott, Kevin C.; Salvalaggio, Paolo; Burroughs, Thomas E.; Gavard, Jeffrey A.; Willoughby, Lisa M.; Lentine, Krista L.

In: Journal of the American Society of Nephrology, Vol. 17, No. 8, 01.08.2006, p. 2299-2306.

Research output: Contribution to journalReview article

Stirnemann, PM, Takemoto, SK, Schnitzler, MA, Brennan, D, Abbott, KC, Salvalaggio, P, Burroughs, TE, Gavard, JA, Willoughby, LM & Lentine, KL 2006, 'Agreement of immunosuppression regimens described in medicare pharmacy claims with the Organ Procurement and Transplantation Network survey', Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2299-2306. https://doi.org/10.1681/ASN.2006030258
Stirnemann, Paula M. ; Takemoto, Steven K. ; Schnitzler, Mark A. ; Brennan, Daniel ; Abbott, Kevin C. ; Salvalaggio, Paolo ; Burroughs, Thomas E. ; Gavard, Jeffrey A. ; Willoughby, Lisa M. ; Lentine, Krista L. / Agreement of immunosuppression regimens described in medicare pharmacy claims with the Organ Procurement and Transplantation Network survey. In: Journal of the American Society of Nephrology. 2006 ; Vol. 17, No. 8. pp. 2299-2306.
@article{1f8078608afd49f38588f1cd765bf933,
title = "Agreement of immunosuppression regimens described in medicare pharmacy claims with the Organ Procurement and Transplantation Network survey",
abstract = "The Organ Procurement and Transplantation Network (OPTN) collects intermittent survey data on immunosuppressive medication use that are studied frequently as research measures. Pharmacy billing claims may provide an accurate measure of immunosuppression use over time. Herein is characterized the agreement of Medicare pharmacy claims for immunosuppressive medications with OPTN reports. Data were drawn from the United States Renal Data System. Participants received a kidney transplant in 2000 to 2001 and had an OPTN record and a Medicare pharmacy claim for an immunosuppressive drug at transplant discharge and 6 mo and 1 yr after transplantation. The concordance (K) of the OPTN and claims (±30 d of survey) for indicated medication use was compared, and sensitivity, specificity, and predictive values for claims were computed, assuming OPTN as a {"}gold standard.{"} Clinical trial participation and regimen changes were examined as explanations for discordance. A total of 4357 eligible subjects were identified. Concordance over observation ranged from excellent for calcineurin inhibitors (κ > 0.86) to generally very good for adjunctive agents (κ = 0.49 to 0.75) to poor for corticosteroids (κ < 0.15). Claims demonstrated high positive predictive values (≤97{\%}) but low negative predictive values (≤13{\%}) for OPTN-reported corticosteroid use. Regimen changes (28 to 75{\%}) but not clinical trial participation (≤21{\%}) were identified frequently among cases with discordant indications of nonsteroid medication use. Close agreement of Medicare billing claims and the OPTN for indicated use of nonsteroid immunosuppressive medications supports both as useful measures of drug exposure. Low detection rates of OPTN-indicated corticosteroid use within claims require further examination.",
author = "Stirnemann, {Paula M.} and Takemoto, {Steven K.} and Schnitzler, {Mark A.} and Daniel Brennan and Abbott, {Kevin C.} and Paolo Salvalaggio and Burroughs, {Thomas E.} and Gavard, {Jeffrey A.} and Willoughby, {Lisa M.} and Lentine, {Krista L.}",
year = "2006",
month = "8",
day = "1",
doi = "10.1681/ASN.2006030258",
language = "English (US)",
volume = "17",
pages = "2299--2306",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - Agreement of immunosuppression regimens described in medicare pharmacy claims with the Organ Procurement and Transplantation Network survey

AU - Stirnemann, Paula M.

AU - Takemoto, Steven K.

AU - Schnitzler, Mark A.

AU - Brennan, Daniel

AU - Abbott, Kevin C.

AU - Salvalaggio, Paolo

AU - Burroughs, Thomas E.

AU - Gavard, Jeffrey A.

AU - Willoughby, Lisa M.

AU - Lentine, Krista L.

PY - 2006/8/1

Y1 - 2006/8/1

N2 - The Organ Procurement and Transplantation Network (OPTN) collects intermittent survey data on immunosuppressive medication use that are studied frequently as research measures. Pharmacy billing claims may provide an accurate measure of immunosuppression use over time. Herein is characterized the agreement of Medicare pharmacy claims for immunosuppressive medications with OPTN reports. Data were drawn from the United States Renal Data System. Participants received a kidney transplant in 2000 to 2001 and had an OPTN record and a Medicare pharmacy claim for an immunosuppressive drug at transplant discharge and 6 mo and 1 yr after transplantation. The concordance (K) of the OPTN and claims (±30 d of survey) for indicated medication use was compared, and sensitivity, specificity, and predictive values for claims were computed, assuming OPTN as a "gold standard." Clinical trial participation and regimen changes were examined as explanations for discordance. A total of 4357 eligible subjects were identified. Concordance over observation ranged from excellent for calcineurin inhibitors (κ > 0.86) to generally very good for adjunctive agents (κ = 0.49 to 0.75) to poor for corticosteroids (κ < 0.15). Claims demonstrated high positive predictive values (≤97%) but low negative predictive values (≤13%) for OPTN-reported corticosteroid use. Regimen changes (28 to 75%) but not clinical trial participation (≤21%) were identified frequently among cases with discordant indications of nonsteroid medication use. Close agreement of Medicare billing claims and the OPTN for indicated use of nonsteroid immunosuppressive medications supports both as useful measures of drug exposure. Low detection rates of OPTN-indicated corticosteroid use within claims require further examination.

AB - The Organ Procurement and Transplantation Network (OPTN) collects intermittent survey data on immunosuppressive medication use that are studied frequently as research measures. Pharmacy billing claims may provide an accurate measure of immunosuppression use over time. Herein is characterized the agreement of Medicare pharmacy claims for immunosuppressive medications with OPTN reports. Data were drawn from the United States Renal Data System. Participants received a kidney transplant in 2000 to 2001 and had an OPTN record and a Medicare pharmacy claim for an immunosuppressive drug at transplant discharge and 6 mo and 1 yr after transplantation. The concordance (K) of the OPTN and claims (±30 d of survey) for indicated medication use was compared, and sensitivity, specificity, and predictive values for claims were computed, assuming OPTN as a "gold standard." Clinical trial participation and regimen changes were examined as explanations for discordance. A total of 4357 eligible subjects were identified. Concordance over observation ranged from excellent for calcineurin inhibitors (κ > 0.86) to generally very good for adjunctive agents (κ = 0.49 to 0.75) to poor for corticosteroids (κ < 0.15). Claims demonstrated high positive predictive values (≤97%) but low negative predictive values (≤13%) for OPTN-reported corticosteroid use. Regimen changes (28 to 75%) but not clinical trial participation (≤21%) were identified frequently among cases with discordant indications of nonsteroid medication use. Close agreement of Medicare billing claims and the OPTN for indicated use of nonsteroid immunosuppressive medications supports both as useful measures of drug exposure. Low detection rates of OPTN-indicated corticosteroid use within claims require further examination.

UR - http://www.scopus.com/inward/record.url?scp=33746486813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746486813&partnerID=8YFLogxK

U2 - 10.1681/ASN.2006030258

DO - 10.1681/ASN.2006030258

M3 - Review article

C2 - 16825328

AN - SCOPUS:33746486813

VL - 17

SP - 2299

EP - 2306

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 8

ER -